Loading company details...
Latest Form 4 (Nov 13, 2026): Frank Torti (President and Vant Chair): Other (see footnotes) of 173,683 shares, $7.02M.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Nov 13, 2026 | Frank Torti, President and Vant Chair | Other (see footnotes) | 173,683 | $7.02M |
| Nov 13, 2026 | Matthew Gline, CEO | Other (see footnotes) | 25,841 | $1.04M |
| Nov 13, 2026 | Mayukh Sukhatme, President & CIO | Other (see footnotes) | 26,152 | $1.06M |
| Nov 13, 2026 | Richard Pulik, CFO | Exercise/Conversion | 125,000 | $481.3K |
| Nov 13, 2026 | Eric Venker, President & Immunovant CEO | Sale | 158,194 | $6.40M |
| Nov 5, 2026 | Eric Venker, President & Immunovant CEO | Sale | 200,000 | $7.26M |
| Oct 30, 2026 | Eric Venker, President & Immunovant CEO | Sale | 200,000 | $7.32M |
| Oct 27, 2026 | Ilan Oren | Grant/Award | 810 | n/a |
| Oct 27, 2026 | Epperly Melissa B, | Grant/Award | 513 | n/a |
| Oct 27, 2026 | James C. Momtazee | Grant/Award | 383 | n/a |